 |
Prospector
Profile
3-25-005
|
| |
| BioDelivery Sciences International, Inc. |
NAICS |
325412 |
| 801 Corporate Center Drive, Suite #210, Raleigh, NC 27607 |
Description |
Pharmaceutical Preparations |
| (919) 582-9050 |
Employees |
21 |
| http://www.bdsinternational.com |
Revenue |
(mil) |
0.2000 |
| |
Income |
(mil) |
-25.1900 |
| |
Assets |
(mil) |
27.9900 |
| |
Liability |
(mil) |
46.7800 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Aidman Piser & Company P.A. raised substantial doubt on BioDelivery Sciences International, Inc.'s ability to continue as a going concern after it audited the Company's financial statements for the year ended December 31, 2007. The auditing firm notes that the Company incurred cumulative net losses of approximately $47.6 million during the two years ended December 31, 2007 and has a stockholders' deficit of approximately $18.8 million as of December 31, 2007. The Company had a net loss of $25.19 million on total revenues of $201,988 for the year ended December 31, 2007, slightly higher than the net loss of $22.39 million on total revenues of $275,778 reported for the year ended December 31, 2006.
|
| |
|
Intellectual Property:
The Company's drug delivery technologies include the patented BEMA(TM) - transmucosal, or applied to the inner cheek mucosa drug delivery technology, and
the patented Bioral(R) cochleate drug delivery technology, designed for a potentially broad base of applications. On August 2, 2006, Arius Two, a newly formed, wholly owned subsidiary of the Company, entered into an Intellectual Property Assignment Agreement and related agreements with QLT USA, Inc., pursuant to which Arius Two purchased intellectual property rights owned by QLT related to its BEMA(TM) technology for territories located outside of the United States. The Company, through its Arius One subsidiary, previously licensed exclusive rights to the BEMA(TM) technology for such territories. [SEC Filing 10-K 03-07-08]
|
| |
|
Description:
BioDelivery Sciences International, Inc. operates as a specialty biopharmaceutical company in the United States.
|
| |
|
Officers:
Francis E. ODonnell, Jr., M.D.(Chair & Dir.); Mark A. Sirgo, Pharm.D. (Pres., CEO & Dir.); Raphael J. Mannino, Ph.D. (EVP, Chief Scientific Officer & Dir.); Andrew L. Finn, Pharm.D. (EVP-Product Development); James A. McNulty (CFO, Sec. & Treas.);
William B. Stone (Lead Dir.); John J. Shea (Dir.); William S. Poole (Dir.); Thomas W. DAlonzo (Dir.)
|
| |
|
Auditor:
Aidman Piser & Company P.A.
|
| |
|
Securities:
Common Stock Symbol BDSI; NasdaqCM; 19,160,637 common shares outstanding as of March 6, 2008.
|
| |
| |
| |
| return to main page |
|
|
